FDA approves Allergan eyelash enhancer
This article was originally published in The Rose Sheet
Executive Summary
Pharmaceutical giant Allergan expects to launch its bimatoprost-based Latisse drug for treating "inadequate" eyelashes (hypotrichosis) in first quarter of 2009. A once-daily prescription treatment applied to the base of the upper eyelashes, "Latisse fulfills a significant and previously unmet need in the medical aesthetic marketplace with a product approved by the FDA that increases the growth of eyelashes, making them longer, thicker and darker," according to Allergan. Results are evident in eight to 16 weeks, firm says, but notes that to maintain luxurious lashes individuals must use the product on a continuing basis, a disclosure recommended by an FDA advisory committee in December (1"The Rose Sheet" Dec. 15, 2008, p. 7). Latisse could bring in $500 million in annual sales, the company says. Like Allergan's blockbuster botulinum toxin type A (Botox) drug, bimatoprost was first approved by FDA as a medical treatment - for patients with glaucoma, among other eye disorders - before its aesthetic benefits were realized. The 13+ years of clinical data supporting bimatoprost could heighten its advantage over eyelash enhancers on the cosmetics market, which sector has been vigilantly policed by Allergan in defense of its patents (2"The Rose Sheet" Jan. 14, 2008, p. 8)
You may also be interested in...
Allergan Continues Legal Sparring With Cosmetic Eyelash-Growth Brands
Latisse marketer Allergan continues to lock horns with cosmetic firms offering non-FDA-approved, prostaglandin-based eyelash-enhancement products, pursuing injunction and damages in California court.
FDA warns Allergan about Latisse claims
FDA's Division of Drug Marketing, Advertising and Communications warned Allergan regarding misleading Web site claims for its Latisse (bimatoprost opthalmic solution) 0.03% eyelash enhancer because the claims "omit and minimize risks" associated with use of the product. The warning was made in a letter dated Sept. 10. Specifically, the pharmaceutical giant failed to communicate that some people are at risk of developing bacterial keratitis, which can be blinding, and that the drug can cause hair to grow in areas other than the eye upon repeated exposure, the agency notes. Based on a drug developed by the company to treat glaucoma, Latisse was approved by FDA in December 2008 as a treatment for "inadequate" eyelashes (1"The Rose Sheet" Jan. 5, 2009). Allergan was advised to respond to the letter by Sept. 24
Allergan Eyelash Growth Drug Wins Over FDA Panel, Steps Closer To Approval
FDA's Dermatologic and Ophthalmic Drugs Advisory Committee voted unanimously (9-0) Dec. 5 to recommend approval of Allergan's eyelash growth-stimulating drug, Latisse